Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Serum Zinc and Iron Levels Reduced in MDD; Copper Levels Elevated

Key Takeaway
Evaluate zinc and iron levels in MDD patients as part of comprehensive care.

This systematic review and meta-analysis evaluated the association between serum levels of zinc, iron, and copper and Major Depressive Disorder (MDD) by analyzing data from 16 observational studies. The primary endpoint was the difference in serum concentrations of these trace elements between MDD patients and healthy controls. Results indicated that individuals with MDD had significantly lower serum zinc (SMD = -0.62; 95% CI: -0.78 to -0.46; I=68.4%) and iron levels (SMD = -0.36; 95% CI: -0.52 to -0.20; I=58.2%), while copper levels were significantly higher (SMD = +0.42; 95% CI: +0.18 to +0.66; I=67.4%). Heterogeneity was moderate to high across studies, and publication bias was noted for zinc and copper, though adjusted estimates for zinc and iron remained significant. No specific safety or adverse events were reported as the study focused on observational data. Clinically, these findings underscore the importance of considering micronutrient status in the pathophysiology and management of depression, suggesting potential avenues for nutritional interventions in psychiatric care. Further research is needed to explore the therapeutic implications of these findings.

AI Accuracy Review: 10/10 · Auto-published
View Original Abstract ↓
INTRODUCTION: Trace elements such as zinc, iron, and copper are integral to neurochemical regulation, oxidative balance, and immune modulation. Their dysregulation has been increasingly implicated in the pathophysiology of Major Depressive Disorder (MDD). This systematic review and meta-analysis aimed to quantify differences in serum levels of zinc, iron, and copper between individuals with MDD and healthy controls. CONTENT: Sixteen observational studies were included following a comprehensive search of major databases. Data on serum concentrations of zinc, iron, and copper were extracted and pooled using a random-effects model. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were calculated. Heterogeneity was assessed using the I statistic, and publication bias was evaluated via funnel plots and Egger's regression. Sensitivity analyses were conducted to test the robustness of findings. SUMMARY: Meta-analysis revealed serum copper levels were significantly higher in patients with MDD compared to controls (SMD = +0.42; 95 % CI: +0.18 to +0.66; I=67.4 %), while zinc (SMD = -0.62; 95 % CI: -0.78 to -0.46; I=68.4 %) and iron (SMD = -0.36; 95 % CI: -0.52 to -0.20; I=58.2 %) were lower in MDD patients. Evidence of publication bias was observed for zinc and copper, but adjusted estimates remained significant for zinc and iron. OUTLOOK: This study demonstrates consistent reductions in serum zinc and iron among individuals with MDD, supporting their potential role in depressive pathophysiology. While copper findings were inconclusive, the stability of zinc and iron results highlights the clinical relevance of micronutrient assessment in depression. These findings provide a foundation for future research in nutritional psychiatry and adjunctive treatment strategies.
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…